One of the most heralded oncology conferences is the annual American Society of Clinical Oncologists (ASCO). This year, Chicago is hosting the annual conference, which is running from May 31st through June 4th. Here are some important fact to be aware of in the coming week.
First, the abstract titles are already available online, and can be viewed on this site by following this link. The titles were released on April 17. The next big date is the release of the abstracts on May 15th. The abstracts will be released to the same website above at 5:00 PM ET. Traditionally, the best way to avoid getting lost in all of the data is to make a list of abstract titles and the abstract number prior to the release of the abstract. Searching the abstract number once the entire abstracts are released will make the process much smoother, allowing you to quickly analyze your holdings’ data and made trades as needed.
Late Breaking Abstracts and Embargo Policy
ASCO does include an embargo policy on certain abstracts. For ASCO, only Late-Breaking Abstracts (LBA) are embargoed, and will not be released on May 15th. The schedule for which LBAs’ embargo is lifted is shown in the figure below.
What constitutes a LBA? The specific guidelines are available here. In summary, trials should be randomized Phase II or Phase III with no preliminary data available at the time of the abstract submission deadline (February 12, 2019). Those submitting the abstract must have a preplanned analysis after February 12th, but before March 14th, which is when the final data is due. The only exception to this March 14th deadline is for Phase III trials, which may receive an extra two week deadline extension.
Selected Abstracts of Interest
Company: Array Biopharma (ARRY)
Abstract #9512: Update on Overall Survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma.
Company: AstraZeneca (AZN)
Abstract #LBA4: Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
Company: Calithera (CALA)
Abstract #7037: Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).
Company: Eli Lilly (LLY)
Abstract #LBA3: ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).
Company: Merck (MRK)
Abstract #LBA9015: Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
Abstract #LBA4007: Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Company: Nektar Therapeutics (NKTR)
Abstract #2623: Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
Company: Novartis (NVS)
Abstract #LBA1008: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.
Company: Roche (RHHBY)
Abstract #3017: Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
Abstract #10009: Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Company: Seattle Genetics (SGEN)
Abstract #LBA4505: EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
Please comment with additional comments/questions or join our StockTwits Room at
This is in no form a recommendation to purchase/sell equities and investors should perform additional due diligence prior to investing.
I/we long ARRY.